US › Healthcare

Fennec Pharmaceuticals Inc (FENC)

US · Healthcare · Biotechnology

$10.11+5.42%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$15.1M
Revenue YoY
+72.6%
Net profit
$201,000
Profit YoY
+117.3%
EPS
$0.01
EPS estimate
$0.03
Net margin
1.3%

EPS came in at 0.01 against a street estimate of 0.03 — a miss of 70.2%.

Key statistics

Market cap
$332.4M
Forward P/E
37.3
P/B
8.81
Book value
$1.09
EPS (TTM)
$-0.29
52-week high
$11.31
52-week low
$5.65
50-day MA
$9.94
200-day MA
$8.23
Beta
1.07

Analyst view

Analysts rate Fennec Pharmaceuticals Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $15.67.

Shareholding

Insiders
14.46%
Institutions
54.33%

Largest institutional holders

FundStake
Rosalind Advisors, Inc.8.37%
Southpoint Capital Advisors LP7.90%
Solas Capital Management LLC7.15%
AIGH Capital Management, LLC5.70%
BlackRock Inc3.94%
Vanguard Capital Management, LLC2.58%
Awm Investment Company Inc2.07%
Geode Capital Management, LLC1.07%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Fennec Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.